• Source: H2-CBD

H2CBD (diHydroCBD, partially hydrogenated CBD) are cannabinoids that were first synthesized by Alexander R. Todd in 1940 by catalytic hydrogenation of cannabidiol.
The term "H2CBD" can refer to two different chemical compounds that differ by the site of hydrogenation, either saturated on the cyclohexenyl ring (i.e. 1,2-dihydrocannabidiol using the older terpenoid numbering scheme) or saturated on the isopropenyl side group, which is known as 8,9-dihydrocannabidiol.
H2CBD, H4-CBD, and 8,9-dihydrocannabidiol have all been referred to as "hydrogenated CBD" which may cause confusion.


<h2>Pharmacologyh2>
In 2006, it was discovered that 8,9-dihydrocannabidiol binds very weakly to the CB1 receptor with a binding affinity higher than 1 μM, but has potential anti-inflammatory effects independent of its cannabinoid receptor action.


<h2>See alsoh2>
Hexahydrocannabinol (hydrogenated THC)
4'-Fluorocannabidiol
7-Hydroxycannabidiol
Abnormal cannabidiol
Cannabidiol dimethyl ether
Delta-6-cannabidiol


<h2>Referencesh2>

Kata Kunci Pencarian:

• Berilium
• H2-CBD
• H4-CBD
• Alec Todd
• Δ-6-Cannabidiol
• Dallas CBD Vertiport
• 8,9-Dihydrocannabidiol
• Cannabinoid
• Progressive supranuclear palsy
• List of airline codes
• Pyrolysis